Sarah Wordsworth
National Institute for Health and Care Research, University of Oxford
Papers
2
Total Citations
100
H-Index
2
About
Sarah Wordsworth is a leading health economist whose work sits at the intersection of clinical trials and health technology assessment, with a primary focus on surgical and ophthalmic interventions. She is best known for her pivotal role in the VIOLET trial, a landmark study comparing video-assisted thoracoscopic surgery (VATS) to open lobectomy for lung cancer. This work, cited 88 times, provided crucial evidence on patient-reported recovery outcomes, directly informing surgical practice and policy. More recently, Wordsworth has driven the STAR trial, a double-masked, sham-controlled investigation of stereotactic radiotherapy for neovascular age-related macular degeneration (nAMD). This innovative device trial, already garnering 12 citations, explores a novel radiation-based alternative to repeated anti-VEGF injections, addressing a major unmet need in ophthalmology. Her research consistently bridges rigorous economic evaluation with patient-centered outcomes, demonstrating how cost-effectiveness and quality-of-life data can shape real-world clinical guidelines. With a career dedicated to generating high-impact evidence for complex interventions, Wordsworth’s work is essential reading for researchers and clinicians seeking to understand the true value of new surgical and therapeutic technologies.
Research Focus
Key Achievements
Top Papers
- 1
- 2